Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends

SAVA
Cassava Sciences Inc
stock NASDAQ

At Close
10/5/2022 3:59:58 PM EDT
40.94USD-1.870%(-0.78)1,020,747
32.84Bid   49.36Ask   16.52Spread IEX
Pre-market
10/5/2022 9:27:30 AM EDT
41.20USD-1.246%(-0.52)0
After-hours
10/5/2022 4:01:30 PM EDT
40.97USD+0.073%(+0.03)0
OverviewOption ChainHistoricalExchange VolumeShort VolumeBorrow FeeFailure to DeliverTrendsNewsMore
open chart   
open chart   
Market Cap
1.642B
Headquarters
Austin, Texas, USA
Industry
Biotechnology
Next Earnings
2022-11-10 (35d)
Last Dividend
2012-12-130.750
Last Split
2017-05-101for7reverse
SAVA Stats
Avg. Vol. 10 Day
3,960,627
Avg. Vol. 30 Day
4,787,983
Employees
24
Market Cap
1,641,608,722
Shares Out.
40,097,917
Float
37,632,296
On/Off Exchange
51%/49%
6 Month Beta
0.50
1 Year Beta
1.17
2 Year Beta
1.57
3 Year Beta
1.33
52 Week Low
13.84
52 Week High
100.00
SMA50
32.41
SMA200
27.13
1 Week
-6.62%
1 Month
+44.36%
3 Month
+54.55%
6 Month
+31.09%
1 Year
-28.39%
2 Year
+253.85%
5 Year
+874.76%
Jan 24, 2022
08:50AM EST  B. Riley Securities Maintains Buy on Cassava Sciences, Lowers Price Target to $72   Benzinga
Jan 14, 2022
12:21PM EST  Cassava Sciences Option Alert: Jan 21 $45 Calls Sweep (4) near the Ask: 80 @ $3.7 vs 1518 OI; Ref=$46.28   Benzinga
Dec 29, 2021
12:07PM EST  Cassava Sciences Whale Trades Spotted   Benzinga
Dec 23, 2021
09:02AM EST  Cassava Sciences Highlights Launch Of Clinical Website To Support Phase 3 Studies Of Oral Simufilam In Alzheimer's Disease   Benzinga
09:00AM EST  -- New website (www.Rethink-ALZ.com) is intended to increase visibility and information for potential study participants. -- Rethink-ALZ.com connects patients with nearest participating clinical site. -- Phase 3 efficacy studies now in over 25 clinical sites across the country.   GlobeNewswire Inc
More News
Profile
Cassava Sciences' mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer's disease.

SAVA Stock Summary

Cassava Sciences Inc (NASDAQ:SAVA) stock price today is $40.94, and today's volume is 1,020,747. SAVA is down -1.870% today. The 30 day average volume is 4,787,983. SAVA market cap is 1.642B with 40,097,917 shares outstanding.



Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter @chartexchange_
ChartExchange on Reddit u/chartexchange
© 2020 - 2022 ChartExchange LLC